Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
• Restoring lost vision
• Potential retina treatment
• Retinal imaging
• CXL safety and efficacy study
• Phase II trial funded
• Regenerative medicines for DR


Survey

Are you in favour of stem cell technology?

Click here to vote

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.

Click here to contact Neil Hanley, sales manager.
September 29, 2010


Restoring vision lost to retinal degeneration
Results from research performed by St Jude Children’s Research Hospital has demonstrated vision lost as a result of glaucoma, diabetic retinopathy and age-related macular degeneration (AMD) may be restored. More...
Potential in retina treatment offered through stem cell research
A stem cell treatment to replace diseased parts of the retina is being pioneered by scientists funded by the Medical Research Council, the Macular Vision Research Foundation and Fight for Sight. More...
Early diagnosis of eye disease with better retinal imaging
Collaborative research has led to the development of an adaptive optics-optical coherence tomography (AO-OCT) system that allows ophthalmologists to see the eye's retina at the individual level. More...
Product Profile
Carl Zeiss Meditec
IOLMaster® 500 - With automatic and non-contact measurement of the patient's eye, the new IOLMaster 500 offers the fastest and easiest way of calculating the right IOL for each patient.

Read more...

Research study into treatment for keratoconus and corneal ectasia
A clinical trial is being conducted by the Cornea and Laser Eye Institute (CLEI) into the efficacy and safety of corneal collagen crosslinking (CXL) using riboflavin/dextran and hypotonic riboflavin in patients with progressive keratoconus and corneal ectasia. More...
FDA grant given for Phase II trial
Applied Genetics Technology Corporation (AGTC) has received a grant from the FDA (FDA Orphan Drugs Programme) to fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Leber congenital amaurosis (LCA), a genetic retinal disease. More...
Development of sight-related stem cell medicine
AstraZeneca and UCL Institute of Ophthalmology are collaborating to develop regenerative medicines for diabetic retinopathy (DR). More...
 

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone
numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other
opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing [email protected] or by mail
at Advanstar Communications Inc., Advanstar House, Park West, Sealand Road, Chester, CH1 4RN United Kingdom